Cspc Pharmaceutical
Cspc Pharmaceutical Group Limited, commonly referred to as Cspc, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Established in 1997, the company has made significant strides in research and development, focusing on innovative drug formulations and high-quality generic medicines. With a strong presence in both domestic and international markets, Cspc operates extensively across Asia, Europe, and North America. Cspc's core offerings include a diverse range of prescription drugs, over-the-counter products, and active pharmaceutical ingredients (APIs). The company is particularly noted for its advancements in oncology, cardiovascular, and central nervous system therapies, setting it apart through its commitment to quality and efficacy. Recognised for its robust market position, Cspc has achieved numerous accolades, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Cspc Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cspc Pharmaceutical's score of 22 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cspc Pharmaceutical's reported carbon emissions
In 2023, Cspc Pharmaceutical, headquartered in Hong Kong, reported total carbon emissions of approximately 1,081,261,000 kg CO2e. This figure includes 663,224,000 kg CO2e from Scope 1 emissions and 418,037,000 kg CO2e from Scope 2 emissions. Over the years, the company has shown a trend of fluctuating emissions, with a notable decrease from 2018's total emissions of about 981,708,420 kg CO2e to 2023 levels. In 2022, Cspc's emissions were approximately 1,137,042,000 kg CO2e, comprising 564,429,000 kg CO2e from Scope 1 and 572,613,000 kg CO2e from Scope 2. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment. Cspc Pharmaceutical's emissions data reflects its operational impact on climate change, and while the company has not set formal reduction targets, its ongoing emissions reporting is crucial for transparency and accountability in its environmental performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 231,562,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 892,873,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cspc Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
